EUVIMEDEUVIMED entdecken
Open Access

Dual COX‐2 and 15‐LOX inhibition study of novel 4‐arylidine‐2‐mercapto‐1‐phenyl‐1 H ‐imidazolidin‐5(4 H )‐ones: Design, synthesis, docking, and anti‐inflammatory activity

Nermine A Osman, Mostafa K Soltan, Samar Rezq, Joseph Flaherty, Damian G Romero, Ahmed S Abdelkhalek

Archiv der Pharmazie · 2024

DOI: 10.1002/ardp.202300615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Nermine A Osman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. Hauptthemen laut MEDLINE: Drug Design, Molecular Docking Simulation, Arachidonate 15-Lipoxygenase, Lipoxygenase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel arylidene‐5(4 H )‐imidazolone derivatives 4a–r were designed and evaluated as multidrug‐directed ligands, that is, inflammatory, proinflammatory mediators, and reactive oxygen species (ROS) inhibitors. All of the tested compounds showed cyclooxygenase (COX)‐1 inhibitory effect more than celecoxib and less than indomethacin and also demonstrated an improved inhibitory activity against 15‐lipoxygenase (15‐LOX). Compounds 4f, 4l , and 4p exhibited COX‐2 selectivity comparable to that of celecoxib, while 4k was the most selective COX‐2 inhibitor. Interestingly, the screened results showed that compound 4k exhibited a superior inhibition effect against 15‐LOX and was found to be the most selective COX‐2 inhibitor over celecoxib, whereas compound 4f showed promising COX‐2 and 15‐LOX inhibitory activities besides its inhibitory effect against ROS production and its lowering effect of both tumor necrosis factor‐α and interleukin‐6 levels by ∼80%. Moreover, compound 4f attenuated the lipopolysaccharide‐mediated increase in NF‐κB activation in RAW 264.7 macrophages. The preferred binding affinity of these molecules was confirmed by docking studies. We conclude that arylidene‐5(4 H )‐imidazolone scaffolds provide promising hits for developing new synthons with anti‐inflammatory and antioxidant activities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignMolecular Docking SimulationArachidonate 15-LipoxygenaseLipoxygenase InhibitorsCyclooxygenase 2 InhibitorsReactive Oxygen SpeciesMiceAnimalsRAW 264.7 CellsStructure-Activity RelationshipMolecular StructureCyclooxygenase 2Dose-Response Relationship, DrugLipopolysaccharidesAnti-Inflammatory Agents, Non-SteroidalAnti-Inflammatory AgentsMacrophagesHumans

Stichwörter der Autor:innen

NF‐κBarylidene‐5(4H)‐imidazolonedual COX‐2/15‐LOX inhibitorsmolecular dockingsynthesis

Substanzen

Arachidonate 15-LipoxygenaseLipoxygenase InhibitorsCyclooxygenase 2 InhibitorsReactive Oxygen SpeciesCyclooxygenase 2LipopolysaccharidesAnti-Inflammatory Agents, Non-SteroidalAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
  • Oman College of Health Sciences, Muscat, Oman.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
  • Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
  • Mississippi Center of Excellence in Perinatal Research, University of Mississippi Medical Center, Jackson, Mississippi, USA.

Förderung

  • NIGMS NIH HHS
  • Foundation for the National Institutes of Health

Zitieren

APA

Osman, N. A., Soltan, M. K., Rezq, S., Flaherty, J., Romero, D. G., & Abdelkhalek, A. S. (2024). Dual COX‐2 and 15‐LOX inhibition study of novel 4‐arylidine‐2‐mercapto‐1‐phenyl‐1 H ‐imidazolidin‐5(4 H )‐ones: Design, synthesis, docking, and anti‐inflammatory activity. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300615

Vancouver

Osman NA, Soltan MK, Rezq S, Flaherty J, Romero DG, Abdelkhalek AS. Dual COX‐2 and 15‐LOX inhibition study of novel 4‐arylidine‐2‐mercapto‐1‐phenyl‐1 H ‐imidazolidin‐5(4 H )‐ones: Design, synthesis, docking, and anti‐inflammatory activity. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300615

BibTeX
@article{Osman2024,
  author = {Osman, Nermine A and Soltan, Mostafa K and Rezq, Samar and Flaherty, Joseph and Romero, Damian G and Abdelkhalek, Ahmed S},
  title = {Dual COX‐2 and 15‐LOX inhibition study of novel 4‐arylidine‐2‐mercapto‐1‐phenyl‐1 H ‐imidazolidin‐5(4 H )‐ones: Design, synthesis, docking, and anti‐inflammatory activity},
  journal = {Archiv der Pharmazie},
  year = {2024},
  doi = {10.1002/ardp.202300615}
}
Kostenlos starten →